Biocide susceptibility of the Burkholderia cepacia complex

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 502-510

  Rose, Helen ^a   Baldwin, Adam ^b   Dowson, Christopher G ^b   Mahenthiralingam, Eshwar ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antibiotics; Minimal inhibitory concentration; Resistance and susceptibility

Indexed keywords

AMIKACIN; AZITHROMYCIN; BENZALKONIUM CHLORIDE; BIOCIDE; CEFTAZIDIME; CETYLPYRIDINIUM SALT; CHLORAMPHENICOL; CHLORHEXIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; MEROPENEM; PIPERACILLIN; POVIDONE; TOBRAMYCIN; TRICLOSAN;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BIOFILM; BROTH DILUTION; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA COMPLEX; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC VARIABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PESTICIDE RESISTANCE; SPECIES DIFFERENCE; SPECIES DIVERSITY; TAXONOMY;

ANTI-BACTERIAL AGENTS; BIOFILMS; BURKHOLDERIA CEPACIA COMPLEX; DISINFECTANTS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 60649103061     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn540     Document Type: Article

References (35)

1. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 2005; 3: 144-56.
2. Govan JR, Brown AR, Jones AM. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2007; 2: 153-64.
3. Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria: Opportunistic pathogens with important natural biology. J Appl Microbiol 2008; 104: 1539-51.
4. Vanlaere E, Lipuma JJ, Baldwin A et al. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol 2008; 58: 1580-90.
5. Vanlaere E, Baldwin A, Gevers D et al. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species: Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol 2009; 59: 102-111.
6. Reik R, Spilker T, Lipuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005; 43: 2926-8.
7. Chernish RN, Aaron SD. Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 2003; 9: 509-15.
8. Henry DA, Campbell ME, LiPuma JJ et al. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997; 35 614-9.
9. Nzula S, Vandamme P, Govan JR. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 2002; 50: 265-9.
10. Jimenez L. Microbial diversity in pharmaceutical product recalls and environments. PDA J Pharm Sci Technol 2007; 61: 383-99.
11. Frank MJ, Schaffner W. Contaminated aqueous benzalkonium chloride. An unnecessary hospital infection hazard. JAMA 1976; 236: 2418-9.
12. Kutty PK, Moody B, Gullion JS et al. Multistate outbreak of Burkholderia cenocepacia colonization and infection associated with the use of intrinsically contaminated alcohol-free mouthwash. Chest 2007; 132: 1825-31.
13. Garcia-Erce JA, Grasa JM, Solano VM et al. Bacterial contamination of blood components due to Burkholderia cepacia contamination from chlorhexidine bottles. Vox Sang 2002; 83: 70-1.
14. Romero-Gomez MP, Quiles-Melero MI, Pena Garcia P et al. Outbreak of Burkholderia cepacia bacteremia caused by contaminated chlorhexidine in a hemodialysis unit. Infect Control Hosp Epidemiol 2008; 29: 377-8.
15. Anderson RL, Vess RW, Carr JH et al. Investigations of intrinsic Pseudomonas cepacia contamination in commercially manufactured povidone-iodine. Infect Control Hosp Epidemiol 1991; 12: 297-302.
16. Baldwin A, Mahenthiralingam E, Drevinek P et al. Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing. J Clin Microbiol 2008; 46: 290-5.
17. Baldwin A, Mahenthiralingam E, Drevinek P et al. Environmental Burkholderia cepacia complex isolates in human infection. Emerg Infect Dis 2007; 13: 458-61.
18. Mahenthiralingam E, Baldwin A, Drevinek P et al. Multilocus sequence typing breathes life into a microbial metagenome. PLoS One 2006; 1: E17.
19. Baldwin A, Mahenthiralingam E, Thickett KM et al. Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex. J Clin Microbiol 2005; 43: 4665-73.
20. Gilbert P, McBain AJ. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin Microbiol Rev 2003; 16: 189-208.
21. Coenye T, Vandamme P, LiPuma JJ et al. Updated version of the Burkholderia cepacia complex experimental strain panel. J Clin Microbiol 2003; 41: 2797-8.
22. Mahenthiralingam E, Coenye T, Chung JW et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol 2000; 38: 910-3.
23. Whiteford ML, Wilkinson JD, McColl JH et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995; 50 1194-8.
24. Lear JC, Maillard JY, Dettmar PW et al. Chloroxylenol- and triclosan-tolerant bacteria from industrial sources. J Ind Microbiol Biotechnol 2002; 29: 238-42.
25. Marchetti MG, Kampf G, Finzi G et al. Evaluation of the bactericidal effect of five products for surgical hand disinfection according to prEN 12054 and prEN 12791. J Hosp Infect 2003; 54 63-7.
26. Stepanovic S, Vukovic D, Dakic I et al. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 2000; 40: 175-9.
27. Coenye T, Spilker T, Van Schoor A et al. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax 2004; 59: 952-4.
28. Coenye T, LiPuma JJ. Multilocus restriction typing: A novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. J Infect Dis 2002; 185: 1454-62.
29. Kalish LA, Waltz DA, Dovey M et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 421-5.
30. Parsek MR, Fuqua C. Biofilms 2003: Emerging themes and challenges in studies of surface-associated microbial life. J Bacteriol 2004; 186: 4427-40.
31. De Soyza A, Silipo A, Lanzetta R et al. Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides. Innate Immun 2008; 14: 127-44.
32. Lambert RJ. Evaluation of antimicrobial efficacy. In: Fraise AP, Lambert PA, Maillard JY, eds. Russell, Hugo and Ayliffe's Principles and Practice of Disinfection, Preservation and Sterilization. Oxford: Blackwell Science Ltd, 2004; 345.
33. Sobel JD, Hashman N, Reinherz G et al. Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med 1982; 73: 183-6.
34. Perry JD, Riley G, Johnston S et al. Activity of disinfectants against Gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis. J Heart Lung Transplant 2002; 21: 1230-1.
35. English DJ. Factors in selecting and testing preservatives in product formulations. In: Orth DS, Kabara JJ, Denyer SP et al., eds. Cosmetic and Drug Microbiology. New York, London: Informa Healthcare, 2006; 57-101.